1. WELCOME AND APOLOGIES

The Chair was replaced by a member, Pieter-Jan Coenraads, who welcomed the participants, in particular representatives from the IDEA project, colleagues from DG GROW and JRC. Five members and external experts from SCCS participated.

2. ADOPTION OF THE AGENDA

The agenda was adopted as presented.

3. DECLARATION OF INTEREST ON MATTERS ON THE AGENDA

The Chair requested participants to declare any conflict of interest regarding matters on the agenda. None of the participants declared any conflict of interest.

4. INFORMATION POINT FROM COMMISSION/CHAIR/MEMBERS

The Commission informed that the announcement of the 3rd IDEA Annual Review Meeting on 16 December 2015 in Luxembourg was placed on the website. See: http://ec.europa.eu/health/scientific_committees/events/ev_20151216_en.htm

5. IDEA-QRA METHODOLOGY

- **Introduction**
  IDEA provided a short introduction of the IDEA project, its aim, organisational structure and the main topics worked on (characterisation of allergens, Pre- and pro haptens and the Quantitative Risk Assessment – QRA - method). More details are available on www.ideaproject.info. Main elements on which the IDEA project had focused with regard to QRA refinement were summarised.

  - **Presentation on the way information regarding the QRA revision had been shared with the Commission / the SCCS - the exchange with the JRC and review work by IDEA.**
  
  The presentation explained in detail the new approach in QRA2 and the main differences to QRA1.
A questions/answers session took place.

- **Presentation on aggregate exposure model and how it is incorporated in the QRA – by IDEA**

  The presentation explained in detail how the aggregate exposure model was incorporated in the QRA. A questions/answers session took place.

- **Presentation from JRC – by JRC**

  JRC summarised the critical review performed by JRC and important observations made. A questions/answers session took place.

**General discussion**

A discussion took place, with a focus on the interface between clinical data and the QRA. Concern was expressed regarding the ‘misuse’ of the model. The SCCS might consider whether the next revision of the SCCS Notes of Guidance should make reference to QRA. SCCS members remain interested in learning about next steps taken. SCCS invited the Commission to send a mandate dealing with the possible use of the model.

6. **ANY OTHER BUSINESS /**

------------------

**Attendance list of experts other than Commission and SCCS working group members:**

IDEA team: Anne Marie Api, Jim Bridges, Damien Comiskey, Graham Ellis, Nicky Gilmour, Helmut Greim, Matthias Vey.